Anti-SERPINA3 and anti-LGALS3BP antibodies in skin cancer research
April 2022 (Institute of Technology, University of Tartu, Nooruse 1, 50411 Tartu, Estonia)
Malignant melanoma is the most severe type of skin cancer with the highest mortality rate.
One possibility for early detection of melanoma is a liquid biopsy (the analysis of tumor-derived biomarkers from peripheral blood such as extracellular vesicles).
A new study analyses the extracellular vesicles isolated from blood serum of patients with melanoma. The results revealed that SERPINA3 and LGALS3BP were higher in melanoma patients than in healthy controls.
The Anti-SERPINA3 (HPA002560) and anti-LGALS3BP (HPA000554) antibodies from Atlas Antibodies were used in western blot assay.
Read more about research: https://lnkd.in/eHhfFbCJ.